CTAG1B

From Wikipedia, the free encyclopedia


Cancer/testis antigen 1B
Identifiers
Symbol(s) CTAG1B; CTAG; CTAG1; ESO1; LAGE-2; LAGE2B; NY-ESO-1; CAMEL; ESO2; LAGE-1; LAGE-2b; MGC138724; MGC3803; LAGE2A
External IDs OMIM: 300156 HomoloGene37469
RNA expression pattern

More reference expression data

Orthologs
Human Mouse
Entrez 1485 n/a
Ensembl ENSG00000126890 n/a
Uniprot O75638 n/a
Refseq NM_001327 (mRNA)
NP_001318 (protein)
n/a (mRNA)
n/a (protein)
Location Chr X: 153.53 - 153.54 Mb n/a
Pubmed search [1] n/a

Cancer/testis antigen 1B, also known as CTAG1B, is a human gene.[1]


[edit] References

[edit] Further reading

  • Scanlan MJ, Gure AO, Jungbluth AA, et al. (2003). "Cancer/testis antigens: an expanding family of targets for cancer immunotherapy.". Immunol. Rev. 188: 22–32. PMID 12445278. 
  • Chen YT, Scanlan MJ, Sahin U, et al. (1997). "A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.". Proc. Natl. Acad. Sci. U.S.A. 94 (5): 1914–8. PMID 9050879. 
  • Chen YT, Boyer AD, Viars CS, et al. (1998). "Genomic cloning and localization of CTAG, a gene encoding an autoimmunogenic cancer-testis antigen NY-ESO-1, to human chromosome Xq28.". Cytogenet. Cell Genet. 79 (3-4): 237–40. PMID 9605863. 
  • Lethé B, Lucas S, Michaux L, et al. (1998). "LAGE-1, a new gene with tumor specificity.". Int. J. Cancer 76 (6): 903–8. PMID 9626360. 
  • Wang RF, Johnston SL, Zeng G, et al. (1998). "A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames.". J. Immunol. 161 (7): 3598–606. PMID 9759882. 
  • De Smet C, Lurquin C, Lethé B, et al. (1999). "DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter.". Mol. Cell. Biol. 19 (11): 7327–35. PMID 10523621. 
  • Schultz-Thater E, Noppen C, Gudat F, et al. (2000). "NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens.". Br. J. Cancer 83 (2): 204–8. doi:10.1054/bjoc.2000.1251. PMID 10901371. 
  • Rimoldi D, Rubio-Godoy V, Dutoit V, et al. (2001). "Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.". J. Immunol. 165 (12): 7253–61. PMID 11120859. 
  • Simpson JC, Wellenreuther R, Poustka A, et al. (2001). "Systematic subcellular localization of novel proteins identified by large-scale cDNA sequencing.". EMBO Rep. 1 (3): 287–92. doi:10.1093/embo-reports/kvd058. PMID 11256614. 
  • Jungbluth AA, Chen YT, Stockert E, et al. (2001). "Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues.". Int. J. Cancer 92 (6): 856–60. doi:10.1002/ijc.1282. PMID 11351307. 
  • Goydos JS, Patel M, Shih W (2001). "NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma.". J. Surg. Res. 98 (2): 76–80. doi:10.1006/jsre.2001.6148. PMID 11397121. 
  • Aradhya S, Bardaro T, Galgóczy P, et al. (2002). "Multiple pathogenic and benign genomic rearrangements occur at a 35 kb duplication involving the NEMO and LAGE2 genes.". Hum. Mol. Genet. 10 (22): 2557–67. PMID 11709543. 
  • Zarour HM, Maillere B, Brusic V, et al. (2002). "NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.". Cancer Res. 62 (1): 213–8. PMID 11782380. 
  • Satie AP, Rajpert-De Meyts E, Spagnoli GC, et al. (2002). "The cancer-testis gene, NY-ESO-1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ.". Lab. Invest. 82 (6): 775–80. PMID 12065688. 
  • Nagata Y, Ono S, Matsuo M, et al. (2002). "Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations.". Proc. Natl. Acad. Sci. U.S.A. 99 (16): 10629–34. doi:10.1073/pnas.112331099. PMID 12138174. 
  • Resnick MB, Sabo E, Kondratev S, et al. (2002). "Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas.". Int. J. Cancer 101 (2): 190–5. doi:10.1002/ijc.10585. PMID 12209997. 
  • Peng LP, Liu HY, Ran YL, et al. (2003). "[Expression of NY-ESO-1 gene in human esophageal carcinoma and its cloning]". Ai Zheng 21 (5): 469–72. PMID 12452034. 
  • Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMID 12477932. 
  • Gnjatic S, Atanackovic D, Jäger E, et al. (2003). "Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses.". Proc. Natl. Acad. Sci. U.S.A. 100 (15): 8862–7. doi:10.1073/pnas.1133324100. PMID 12853579.